TY - JOUR
T1 - Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines
T2 - A Systematic Review and Meta-Analysis
AU - Titus, Anoop
AU - Cheema, Huzaifa Ahmad
AU - Shafiee, Arman
AU - Seighali, Niloofar
AU - Shahid, Abia
AU - Bhanushali, Karan B.
AU - Kumar, Ashish
AU - Khan, Safi U.
AU - Khadke, Sumanth
AU - Thavendiranathan, Paaladinesh
AU - Hundley, W. Gregory
AU - Scherrer-Crosbie, Marielle
AU - Nohria, Anju
AU - Neilan, Tomas G.
AU - Dani, Sourbha S.
AU - Nasir, Khurram
AU - Ganatra, Sarju
N1 - Funding Information:
Funding: No financial support was received for this study.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/10
Y1 - 2023/10
N2 - Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.
AB - Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.
UR - http://www.scopus.com/inward/record.url?scp=85164336037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164336037&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2023.101885
DO - 10.1016/j.cpcardiol.2023.101885
M3 - Review article
C2 - 37336312
AN - SCOPUS:85164336037
SN - 0146-2806
VL - 48
SP - 101885
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 10
M1 - 101885
ER -